This table presents recent patent oppositions filed by Teva Pharmaceutical Industries, Ltd. against its competitors. It outlines key details of each case, including the patent title, filing date and the applicant. This information provides insights into the competitive landscape and highlights active disputes over patent grant within the industry.

Patent NumberTitleApplicantOpposition Date
EP4159204Novel Pharmaceutical CompositionNOVARTIS AGNov 13, 2024
EP2395968Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM INTERNATIONAL GMBHOct 16, 2024
EP2501384Method Of Treating Proliferative Disorders And Other Pathological Conditions Mediated By Bcr-Abl, C-Kit, Ddr1, Ddr2 Or Pdgf-R Kinase ActivityNOVARTIS AGNov 17, 2016

The following table provides an overview of the latest patents of Teva Pharmaceutical Industries, Ltd. that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3050556Mar 22, 2017Process For Manufacturing A Pharmaceutical Preparation Containing Glatiramer Acetate3